Amylyx Pharmaceuticals, Inc. AMLX Additional Paid-In Capital
Additional Paid-In Capital at other companies
Other financials
Where this comes from
Reported directly by Amylyx Pharmaceuticals, Inc. in its filing.
Tagged under the XBRL concept us-gaap:AdditionalPaidInCapitalCommonStock.
The official record: Amylyx Pharmaceuticals, Inc.’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →
Ask your AI about Amylyx Pharmaceuticals, Inc.'s additional paid-in capital.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Amylyx Pharmaceuticals, Inc.'s additional paid-in capital?
- Amylyx Pharmaceuticals, Inc. (AMLX) reported additional paid-in capital of $1.07B in Q1 2026.
- How has Amylyx Pharmaceuticals, Inc.'s additional paid-in capital changed year-over-year?
- Amylyx Pharmaceuticals, Inc.'s additional paid-in capital increased by 26.3% year-over-year, from $844.01M to $1.07B.
- What is the long-term trend for Amylyx Pharmaceuticals, Inc.'s additional paid-in capital?
- Over 4 years (2021 to 2025), Amylyx Pharmaceuticals, Inc.'s additional paid-in capital has grown at a 287.9% compound annual growth rate (CAGR), from $4.67M to $1.06B.
- What does additional paid-in capital mean?
- Capital received from shareholders in excess of par value — the premium investors paid over the nominal value of shares at issuance, plus stock-based compensation effects.